Background: Human serum paraoxonase-1 (PON-1)
hydrolyzes organophosphate compounds (OPC) and so
significantly alters an individual‘s susceptibility to the toxicity of
these chemicals. Aim: The study was designed to assess the
serum PON-1 activity in patients with OPC poisoning and to
correlate its level with the severity and outcome of acutely
organophosphate poisoned patients. Patients and methods:
This was a prospective clinical study that was performed at Benha
Poison Treatment and Toxicological Research Unit (BPTTRU),
Benha University Hospitals, Egypt, for one year, from 1 August
2020 till 31 July 2021. Patients were divided into case and control
groups. Socio-demographic information of patients, clinical
findings, treatments given, length of hospital stay and outcome
were collected into datasheets. Patients were classified according
to degree of toxicity according to Peradeniya Organophosphorus
Poisoning (POP) scale. Blood samples were collected from
patients to assess pseudocholiesterase and PON-1 activities.
Results: Reduction of serum pseudocholinesterase and
paraoxonase-1 (PON-1) activities in poisoned patients and
patients can be graded according to (POP) scale into: mild,
moderate and severe cases. In conclusion: This study concluded
that serum paraoxonase-1 (PON-1) activity was significantly
lower in patients with severe organophosphorus compounds
(OPC) poisoning as compared to patients with moderate
poisoning. Lower PON-1 activity was significantly associated
with lower serum cholinesterase and poorer outcomes. PON-1
activity may be considered as an indicator of prognosis in OPC
poisoning.
|
